GlobeNewswire

Forward Therapeutics Announces U.S. FDA IND Clearance to Initiate Phase 2 Study of FT2109 in Psoriatic Arthritis
05/11/2026
BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Forward Therapeutics, Inc. (“Forward” or the “Company”), a clinical-stage biotechnology company developing oral small molecule therapies for inflammation-driven diseases, today [...]
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
05/11/2026
VERO BEACH, FL, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company advancing differentiated therapeutic programs for [...]
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in November
05/11/2026
NORWOOD, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive [...]
Galectin Therapeutics Presents New Analyses on Noninvasive Prediction of Variceal Development from its Belapectin Development Program at AASLD Liver Meeting 2026
05/11/2026
Galectin Therapeutics will present new clinical findings at American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Denver. These results will be covered in one oral presentation and two posters [...]
Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026
05/11/2026
SYDNEY, AUSTRALIA, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today [...]
Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
05/11/2026
MORRISTOWN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 receptor agonist, in serious liver [...]
Baird Medical and Alpmed Announce FDA 510(k) and EU CE Submissions for Irreversible Electroporation (IRE) System
05/11/2026
510(k) Application to U.S. Food and Drug Administration and Application for European Union Certification Submitted in Fourth Quarter 2026 NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings [...]
Shattuck Labs Reports Third Quarter 2026 Financial Results and Recent Business Highlights
05/11/2026
– Initiated the RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in Crohn’s disease; 12-week induction data expected in the first half of 2028 – – Announced RECEPTIVE-HS1 Phase 2 clinical trial of SL-325 in hidradenitis [...]
PharmAla Signs Agreement and Initiates R&D with Corealis Pharma for GMP Manufacturing of its patented ALA-002 Drug Product
05/11/2026
TORONTO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development and manufacturing of MDXX- [...]
Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences
05/11/2026
ALAMEDA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics” or “the Company”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR [...]
Verrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
05/11/2026
WEST CHESTER, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of [...]
Novastra Therapeutics Establishes Scientific Advisory Board and Appoints Senior Advisors and Head of Clinical Development
05/11/2026
Experts in immuno-oncology, medical oncology, clinical development, and regulatory affairs to guide and support advancement of OmniAntigen™ Platform (OAP) programs OAP enables systematic immune reprogramming therapy ( [...]
Ovid Therapeutics to Participate in Upcoming Investor Conferences
05/11/2026
NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today [...]
SpyGlass Pharma to Participate in Upcoming Investor Conferences
05/11/2026
IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the executive management [...]
Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12
05/11/2026
DALLAS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]
Science 37 Named 2026 “BioTechnology Innovation of the Year” for its Direct-to-Patient Clinical Trial Delivery Model
05/11/2026
The BioTech Breakthrough Award recognizes Science 37’s Direct-to-Patient Site model for expanding patient access and delivering measurable clinical trial performance nationwide MORRISVILLE, N.C., Nov. 05, 2026 (GLOBE [...]
MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines
05/11/2026
Ghent, Belgium – November 5, 2026, Nov. 05, 2026 (GLOBE NEWSWIRE) -- MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines Collaboration [...]
Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
05/11/2026
CHARLESTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac [...]
Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis
05/11/2026
New INTEGUMENT-3 study to evaluate efficacy, safety, and tolerability of investigational ZORYVE® cream 0.3% in individuals with moderate to severe atopic dermatitis Study aims to expand once-daily ZORYVE cream treatment [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum